Immune-related Colitis Induced by the Long-term Use of Nivolumab in a Patient with Non-small Cell Lung Cancer

被引：24
|
作者：
Yasuda, Yuichiro [1 ]
Urata, Yoshiko [1 ]
Tohnai, Rie [1 ]
Ito, Shoichi [1 ]
Kawa, Yoshitaka [1 ]
Kono, Yuko [1 ]
Hattori, Yoshihiro [1 ]
Tsuda, Masahiro [2 ]
Sakuma, Toshiko [3 ]
Negoro, Shunichi [1 ]
Satouchi, Miyako [1 ]
机构：
[1] Hyogo Canc Ctr, Dept Thorac Oncol, Akashi, Hyogo, Japan
[2] Hyogo Canc Ctr, Dept Gastroenterol Oncol, Akashi, Hyogo, Japan
[3] Hyogo Canc Ctr, Dept Diagnost Pathol, Akashi, Hyogo, Japan
来源：
INTERNAL MEDICINE | 2018年 / 57卷 / 09期
关键词：
nivolumab; immune-related adverse event; colitis; non-small cell lung cancer; immune-checkpoint-inhibitor; MANAGEMENT; DOCETAXEL; BLOCKADE;
D O I：
10.2169/internalmedicine.9230-17
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
We herein report a case of immune-related colitis induced by the long-term use of nivolumab. A 62-year-old Japanese man was treated with nivolumab at 3 mg/kg every 2 weeks for advanced lung adenocarcinoma. The patient was admitted to our hospital due to non-bloody watery diarrhea after the 70th dose of nivolumab. A biopsy specimen of the colon mucosa revealed evidence of colitis with cryptitis and crypt microabscesses. He was diagnosed with immune-related colitis and started on predonisolone 60 mg/day. Subsequently, his symptoms remarkably resolved. Consideration of immune-related adverse events up to several years after the initiation of nivolumab is important.
引用
收藏
页码：1269 / 1272
页数：4
相关论文
共 50 条
  • [1] An autopsy case of immune-related severe colitis due to long-term use of nivolumab in a patient with non-small cell lung cancer
    Fujikawa, Masashi
    Tajiri, Tomoko
    Takemura, Masaya
    Nakao, Kenju
    Yamamoto, Sayaka
    Takeda, Norihisa
    Fukumitsu, Kensuke
    Fukuda, Satoshi
    Kamemitsu, Yoshihiro
    Uemura, Takehiro
    Ohkubo, Hirotsugu
    Maeno, Ken
    Ito, Yutaka
    Oguri, Tetsuya
    Niimi, Akio
    RESPIRATORY MEDICINE CASE REPORTS, 2022, 39
  • [2] Immune thrombocytopenia induced by nivolumab in a patient with non-small cell lung cancer
    Mori, Hidenori
    Sakai, Chizuru
    Iwai, Masamichi
    Sasaki, Yuka
    Gomyo, Takenobu
    Toyoshi, Sayaka
    Kaito, Daizo
    Yanase, Komei
    Ito, Fumitaka
    Endo, Junki
    Funaguchi, Norihiko
    Ohno, Yasushi
    Minatoguchi, Shinya
    RESPIRATORY MEDICINE CASE REPORTS, 2019, 28
  • [3] Durvalumab-induced Immune-related Hepatitis in a Patient with Non-small Cell Lung Cancer
    Nakamura, Masakatsu
    Otsuka, Toshimi
    Hayashi, Ranji
    Horita, Tomoe
    Ota, Masafumi
    Sakurai, Naoko
    Takano, Hikaru
    Hayashi, Tasuku
    Kumagai, Motona
    Yamada, Sohsuke
    Arisawa, Tomiyasu
    INTERNAL MEDICINE, 2020, 59 (21) : 2711 - 2717
  • [4] Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small Cell Lung Cancer
    Haratani, Koji
    Hayashi, Hidetoshi
    Chiba, Yasutaka
    Kudo, Keita
    Yonesaka, Kimio
    Kato, Ryoji
    Kaneda, Hiroyasu
    Hasegawa, Yoshikazu
    Tanaka, Kaoru
    Takeda, Masayuki
    Nakagawa, Kazuhiko
    JAMA ONCOLOGY, 2018, 4 (03) : 374 - 378
  • [5] Immune Thrombocytopenia Induced by Nivolumab in a Metastatic Non-Small Cell Lung Cancer Patient
    Karakas, Yusuf
    Yuce, Deniz
    Kilickap, Saadettin
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 (10) : 621 - +
  • [6] Eltrombopag olamine for refractory immune-related thrombocytopenia induced by pembrolizumab in a non-small cell lung cancer patient
    Ito, Munehiro
    Kanda, Shintaro
    Yoshida, Tatsuya
    Okuma, Yusuke
    Jo, Hitomi
    Fukuhara, Suguru
    Maeshima, Akiko Miyagi
    Ohe, Yuichiro
    LUNG CANCER, 2020, 146 : 362 - 365
  • [7] Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab
    Sato, Koichi
    Akamatsu, Hiroaki
    Murakami, Eriko
    Hayata, Atsushi
    Tokudome, Nahomi
    Akamatsu, Keiichiro
    Koh, Yasuhiro
    Ueda, Hiroki
    Nakanishi, Masanori
    Yamamoto, Nobuyuki
    ANNALS OF ONCOLOGY, 2017, 28 : 86 - 86
  • [8] Correlation Between Immune-Related Adverse Events and Efficacy in Non-Small Cell Lung Cancer Treated with Nivolumab
    Sato, K.
    Akamatsu, H.
    Eriko, M.
    Sakaki, S.
    Kanai, K.
    Hayata, A.
    Tokudome, N.
    Akamatsu, K.
    Koh, Y.
    Ueda, H.
    Nakanishi, M.
    Yamamoto, N.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2428 - S2429
  • [9] Association between immune-related adverse events and efficacy of nivolumab in advanced non-small cell lung cancer
    Usui, Yuko
    Udagawa, Hibiki
    Kirita, Keisuke
    Umemura, Shigeki
    Matsumoto, Shingo
    Yoh, Kiyotaka
    Niho, Seiji
    Goto, Koichi
    ANNALS OF ONCOLOGY, 2017, 28
  • [10] Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab
    Sato, Koichi
    Akamatsu, Hiroaki
    Murakami, Eriko
    Sasaki, Seigo
    Kanai, Kuninobu
    Hayata, Atsushi
    Tokudome, Nahomi
    Akamatsu, Keiichiro
    Koh, Yasuhiro
    Ueda, Hiroki
    Nakanishi, Masanori
    Yamamoto, Nobuyuki
    LUNG CANCER, 2018, 115 : 71 - 74
12345